SODIUM NITROPRUSSIDE ANHYDROUS

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	5CN.Fe.NO.2Na
Molecular Weight	261.918
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of SODIUM NITROPRUSSIDE ANHYDROUS

Structure Search

SMILES

[Na+].[Na+].[Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+]

InChI

InChIKey=XEYBHCRIKKKOSS-UHFFFAOYSA-N

InChI=1S/5CN.Fe.NO.2Na/c5*1-2;;1-2;;/q5*-1;+2;3*+1

HIDE SMILES / InChI

Molecular Formula	CHN
Molecular Weight	27.0253
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Fe
Molecular Weight	55.845
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	NO
Molecular Weight	30.0061
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19538173https://www.drugs.com/pro/sodium-nitroprusside.html | https://www.ncbi.nlm.nih.gov/pubmed/7598246https://www.ncbi.nlm.nih.gov/pubmed/8644642 | https://www.ncbi.nlm.nih.gov/pubmed/7504768 | https://www.ncbi.nlm.nih.gov/pubmed/1724528 | https://adisinsight.springer.com/drugs/800001151https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19601018&CC=US&NR=2957021A&KC=A | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20020124&CC=WO&NR=0205795A2&KC=A2http://www.ncbi.nlm.nih.gov/pubmed/6985697https://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19732062 | https://www.ncbi.nlm.nih.gov/pubmed/28988245 | https://www.ncbi.nlm.nih.gov/pubmed/24923291 | https://www.ncbi.nlm.nih.gov/pubmed/19563531https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/9845803http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdfwww.ncbi.nlm.nih.gov/pubmed/24071762
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/13106442

Pentaerythritol tetranitrate is an organic nitrate that has been used for the treatment of angina pectoris. Upon administration, the drug undergoes exstensive metabolism to NO which causes vasodilation and the relaxation of smooth muscle cells. The compound belongs to a familiy of explosive substances and may be used accordingly.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
liberation of NO 20 Target ID: liberation of NO Sources: http://www.ncbi.nlm.nih.gov/pubmed/2242448	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: www.ncbi.nlm.nih.gov/pubmed/18574453	Activator 1447	0.1 µM [EC50]
nitric oxide mediated signal transduction 20 Target ID: GO:0007263 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23927471	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24560804	Activator 1447
Atrial natriuretic peptide receptor A 21 Target ID: CHEMBL1988 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12419094	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10553632	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdf	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: https://www.google.com/patents/EP2805730A1	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12700285	Primary	Preclinical	Unknown Approved Use Unknown
Hypertensive crises 20 Sources: https://www.drugs.com/pro/sodium-nitroprusside.html#s-34067-9	Primary	Approved 8583	NIPRIDE Approved Use Sodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure. Launch Date 1974
Heart failure 106 Sources: https://www.drugs.com/pro/sodium-nitroprusside.html#s-34067-9	Primary	Approved 8583	NIPRIDE Approved Use Sodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure. Launch Date 1974
Pulmonary hypertension 32 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdf	Palliative	Approved 8583	INOMAX Approved Use INOmax is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. Launch Date 1999
Angina pectoris 110 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdf	Primary	Approved 8583	DILATRATE-SR Approved Use dilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date 1998
Angina pectoris 110 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdf	Primary	Approved 8583	MONOKET Approved Use monoket® is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date 1993
Angina pectoris 110 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16644612	Primary	Approved 8583	Unknown Approved Use Unknown
Coronary heart disease 43 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2242448	Primary	Basic research	Unknown Approved Use Unknown
Angina 34 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8583	NITROSTAT Approved Use Acute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris. Launch Date 2000
Myocardial infarction 125 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8583	NITROGLYCERIN Approved Use Management of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI. Launch Date 1981
Hypertension 575 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8583	NITROGLYCERIN Approved Use IV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures. Launch Date 1981
Heart failure 106 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8583	NITROGLYCERIN Approved Use IV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states. Launch Date 1981
Angina pectoris 110 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4284102 https://www.ncbi.nlm.nih.gov/pubmed/13271134 https://www.ncbi.nlm.nih.gov/pubmed/13426891 https://www.ncbi.nlm.nih.gov/pubmed/13284675	Primary	Approved 8583	Metamine Approved Use https://www.ncbi.nlm.nih.gov/pubmed/13426891 \| https://www.ncbi.nlm.nih.gov/pubmed/13284675
Angina pectoris 110 Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1952976/pdf/brmedj02877-0002.pdf	Primary	Approved 8583	PERITRATE Approved Use Unknown

C_max

Value	Dose	Analyte	Population
187 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
356 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
388 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
557 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1151 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:	GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.7 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:	NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
79 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
35 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
15 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
29.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.89 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.03 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.26 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.08 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
32 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
37 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
32 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
34 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
8 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
1458 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2647 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2524 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6979 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14241 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3380 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:	GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12.3 pg × min/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:	NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
106.5 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
31.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12.2 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.4 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.54 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.5 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.46 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.11 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
311 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
423 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
60 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
61 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
335 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
310 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
49 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
70 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
303 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
50 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:	GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
40 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:	NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2 min REVIEW https://pubmed.ncbi.nlm.nih.gov/6375932/	single, intravenous	NITROPRUSSIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.7 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.2 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.6 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.8 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% EXPERIMENT https://www.sciencedirect.com/science/article/pii/B9780128012383967114			ISOSORBIDE DINITRATE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:		MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 MRP2 499 K+ channels 73 Ca2+ channels 59 ALDH2 21	ALDH2 21 CYP1A2 1197 CYP2A6 626 CYP2E1 729 CYP4A11 137	OCT1 39

Drug as perpetrator

Target	Modality	Activity
ALDH2 21	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15331769/	no
K+ channels 73	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S001429990800616X Page: abstract	no
Ca2+ channels 62	inhibitor 4027 Sources: https://link.springer.com/article/10.1007/BF00497774 Page: abstract	yes
MRP2 625	inhibitor 4027 Sources: https://www.ingentaconnect.com/content/ben/dml/2011/00000005/00000001/art00009 Page: abstract	yes
OCT1 656	inducer 1966 Sources: https://www.sciencedirect.com/science/article/abs/pii/S1056871913002578 Page: abstract	yes
P-gp 1932	inhibitor 4027 Sources: https://www.nature.com/articles/aps201225 Page: abstract	yes

Drug as victim

Target	Modality	Activity
CYP3A4 1946	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	major
CYP1A2 1197	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP2A6 626	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP2C9 1193	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP2D6 1388	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP2E1 729	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP4A11 137	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
ALDH2 21	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15331769/	no

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6061	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6061
ChemicalBook	CB2226929	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2226929
eMolecules	30154680	https://www.emolecules.com/cgi-bin/more?vid=30154680
eMolecules	33507015	https://www.emolecules.com/cgi-bin/more?vid=33507015
eMolecules	36753592	https://www.emolecules.com/cgi-bin/more?vid=36753592
eMolecules	524496	https://www.emolecules.com/cgi-bin/more?vid=524496
ZINC	ZINC000018089317	http://zinc15.docking.org/substances/ZINC000018089317
ChEBI	CHEBI:6062	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6062
ChemicalBook	CB3256697	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3256697
eMolecules	30488208	https://www.emolecules.com/cgi-bin/more?vid=30488208
eMolecules	713614	https://www.emolecules.com/cgi-bin/more?vid=713614
MolPort	MolPort-003-848-286	https://www.molport.com/shop/molecule-link/MolPort-003-848-286
ZINC	ZINC000001849548	http://zinc15.docking.org/substances/ZINC000001849548
ChEBI	CHEBI:28787	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28787
ChemicalBook	CB2145318	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2145318
ZINC	ZINC000008214625	http://zinc15.docking.org/substances/ZINC000008214625
AA Blocks	AA00ILEO	https://www.aablocks.com/goods/Goods/detail?id=AA00ILEO
Aaron Chemicals	AR00IM6G	http://www.aaronchem.com/1302-78-9
Alfa Chemistry	7077-34-1	https://www.alfa-chemistry.com/cas_7077-34-1.htm
Ambinter	Amb17672903	http://www.ambinter.com/reference/17672903
BioSynth	W-111015	https://www.biosynth.com/en/products/chemical-intermediates/basic-intermediates/products/W-111015.html
Chemspace	CSSB00016996527	https://chem-space.com/CSSB00016996527
Clearsynth	CS-O-00951	http://www.clearsynth.com/en/CSO00951.html
Lab Network	LN02049364	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN02049364
Oakwood	94458	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=79632&ExtHyperLink=1
Smolecule	S585822	https://www.smolecule.com/products/s585822
THE BioTek	bt-433598	https://www.thebiotek.com/product/others/bt-433598
ChEBI	CHEBI:7596	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7596
eMolecules	10397191	https://www.emolecules.com/cgi-bin/more?vid=10397191
3B Scientific (Wuhan) Corp	3B2-4956	http://www.3bsc.com/index/pro_info.php?id=79896
3B Scientific (Wuhan) Corp	3B3-046180	http://www.3bsc.com/index/pro_info.php?id=82779
ABI Chem	AC1L1MPG
ABI Chem	AC1Q21X4
AHH Chemical co.,ltd	MT-57727	http://www.ahhchemical.com/product/MT-57727.html
AN PharmaTech	AN-23936
Chemhere	Achem162548
Chemieliva Pharmaceutical Co., Ltd	PBCM0000174
ChemMol	49416736	http://www.chemmol.com/chemmol/49416736.html
ChemMol	99151477	http://www.chemmol.com/chemmol/99151477.html
Compound Cloud	6518
Hangzhou Yuhao Chemical Technology	LL0106
LGC Standards	DRE-LA15589000AL	https://www.lgcstandards.com/US/en/p/DRE-LA15589000AL
NovoSeek	6518
SelectLab Chemicals GmbH	Ex187
Sigma-Aldrich	ERP-109S_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/erp109s?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	P-037_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/p037?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma Aldrich	ERP-109S
Sigma Aldrich	P-037
Smolecule	S567259	https://www.smolecule.com/products/s567259
Tetrahedron	TS61261
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.	PH-0472
Yuhao Chemical	LL0106	http://www.chemyuhao.com/78-11-5.html
ZINC	ZINC000008101167	http://zinc15.docking.org/substances/ZINC000008101167

PubMed

Title	Date	PubMed
Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.	1990 Jun	1694912
Baroreflex changes produced by serotonergic or catecholaminergic lesions in the rat nucleus tractus solitarius.	1992 Apr	1560369
Bradykinin-induced activation of nociceptors: receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro.	1992 Dec	1334751
Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs.	1992 Jan	1346487
Pirsidomine, a novel nitric oxide donor, suppresses ischemic arrhythmias in anesthetized pigs.	1993	7504768
Effectiveness of an NO-releasing pirsidomine derivative on coronary conductance during long-term administration.	1993	7504764
The sydnonimine C87-3754 evokes endothelium-independent relaxations and prevents endothelium-dependent contractions in blood vessels of the dog.	1993	7504762
Potentiation of retinoic acid-induced U-937 differentiation into respiratory burst-competent cells by nitric oxide donors.	1995 May	7769833
Nitric oxide inhibits HIV tat-induced NF-kappaB activation.	1999 Jul	10393859
Suppression of heme oxygenase-1 mRNA expression by interferon-gamma in human glioblastoma cells.	1999 Jun	10349844
[The effects of sodium nitroprusside-induced hypotension at different levels on cerebral blood flow and metabolism: a clinical study].	2000 Aug	12903451
Local 42 degrees C hyperthermia improves vascular conductance of the R3230Ac rat mammary adenocarcinoma during sodium nitroprusside infusion.	2000 Aug	10931692
Bupivacaine inhibits baroreflex control of heart rate in conscious rats.	2000 Jan	10638917
The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke.	2001	11306778
The use of intravenous nitroglycerin in a case of spasm of the sphincter of Oddi during laparoscopic cholecystectomy.	2001 Apr	11379694
Treatment of anal fissure with glyceryl trinitrate in patients referred for surgical management.	2001 Apr	11355729
Nonadrenergic, noncholinergic relaxation of human isolated corpus cavernosum induced by scorpion venom.	2001 Apr	11306421
Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis.	2001 Apr	11256976
Cardiac natriuretic peptides--hope or hype?	2001 Feb	11286604
Continued cigarette smoking after coronary artery bypass surgery reduces endothelium-dependent vasodilation in internal thoracic artery grafts.	2001 Feb	11256542
Insulin resistance adds to endothelial dysfunction in hypertensive patients and in normotensive offspring of subjects with essential hypertension.	2001 Feb	11240849
Oxytocics reverse the tocolytic effect of glyceryl trinitrate on the human uterus.	2001 Feb	11236116
Acute myocardial infarction secondary to coronary vasospasm during withdrawal from industrial nitroglycerin exposure--a case report.	2001 Feb	11228088
Enhanced 99Tc(m)-MIBI SPECT detection of hibernating myocardium following the use of sub-lingual nitroglycerine.	2001 Jan	11233554
Pseudonormal diastolic filling unmasked with glyceryl trinitrate in patients with type 2 diabetes with poor metabolic control.	2001 Jul	11423529
Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions.	2001 Jul 2	11420146
Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women.	2001 Jun	11397846
Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.	2001 Jun	11376633
Nitric oxide in primary headaches.	2001 Jun	11371754
Ecstasy induced acute myocardial infarction.	2001 Jun	11359764
Technique for using video microscopy and indicator dilution for repeated measurements of cardiac output in small animals.	2001 Mar	11374611
Comparison of provocative tests for unexplained syncope: isoprenaline and glyceryl trinitrate for diagnosing vasovagal syncope.	2001 Mar	11237545
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction.	2001 Mar 12	11231708
Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria.	2001 May	11380077
Glyceryl trinitrate ointment as a potential treatment for primary vaginismus.	2001 May	11311772
Heart preservation with celsior solution improved by the addition of nitroglycerine.	2001 May 27	11391222
Treatment of chronic anal fissure with topical glyceryl trinitrate: a double-blind, placebo-controlled trial.	2001 May-Jun	11400799
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.	2003 Apr	12700285
JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.	2003 Dec	14566972
Sodium nitroprusside-induced deliberate hypotension to facilitate patent ductus arteriosus ligation in dogs.	2003 Jul-Aug	12865995
Hypothermia does not alter somatosensory evoked potential amplitude and global cerebral oxygen extraction during marked sodium nitroprusside-induced arterial hypotension.	2003 May	12717132
Receptor activity modifying protein 2 distribution in the rat central nervous system and regulation by changes in blood pressure.	2003 Sep	12899678
Additive antinociceptive effect of the combination of diazoxide, an activator of ATP-sensitive K+ channels, and sodium nitroprusside and dibutyryl-cGMP.	2004 Apr 5	15063156
Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function.	2004 Feb	14718356
S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis.	2006 Nov 10	16980304
Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator.	2006 Oct	17050951
Melittin inhibits inflammatory target gene expression and mediator generation via interaction with IkappaB kinase.	2007 Jan 15	17067557
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.	2007 Jul 15	17384201
Compromised aortic vasoreactivity in male estrogen receptor-alpha-deficient mice during acute lipopolysaccharide-induced inflammation.	2007 Mar	17158209
Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia.	2013	23418481

Patents

Sample Use Guides

In Vivo Use Guide

mice were treated three times a week for 3 weeks with intravenous tail vein injections of either vehicle (2.25% Pluronic P123 in PBS) or JS-K (6 μmol/kg in the vehicle).

Route of Administration: Intravenous

In Vitro Use Guide

Human U87 cells (HTB-14), fibroblasts (CRL-1634), and astrocytes (CRL-8621; ATCC) were cultured in Dulbecco’s Minimal Essential Eagle Medium (DMEM; Gibco, USA) supplemented with 10% fetal calf serum (FCS) and penicillin (100U/mL)/streptomycin (100mg/mL) under normoxic conditions (95% air, 5% CO2, and 37°C). The nitric oxide donor JS-K (O2-(2.4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl] diazen-1-ium1,2-diolate, CAS 7054 32-12-8) was dissolved in 100% dimethyl sulfoxide (DMSO) in a concentration of 5.2mM. U87 was incubated with JS-K doses of 0–15µM for 4 h. The JS-K solvent control (DMSO≤1%) was adjusted to the highest JS-K concentration used in these experiments. A cesium source emitting γ-radiation was used for radiotherapy (RT; 3×2Gy) with a 24-h interval between each RT dose (Isotopen Diagnostik CIS, Germany).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:10:03 GMT 2025` Edited by `admin` on `Mon Mar 31 21:10:03 GMT 2025`
Record UNII	XN654NKH9W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NITROPRUSSIDE SODIUM

Preferred Name

English

SODIUM NITROPRUSSIDE ANHYDROUS

Common Name

English

SODIUM NITROPRUSSIDE [MI]

Common Name

English

DISODIUM PENTACYANONITROSYLFERRATE(2-)

Common Name

English

FERRATE(2-), PENTAKIS(CYANO-C)NITROSYL-, DISODIUM, (OC-6-22)-

Common Name

English

SODIUM NITROFERRICYANIDE

Common Name

English

Nitroprusside sodium [WHO-DD]

Common Name

English

Code System Code Type Description

EVMPD

SUB12302MIG